Kawasumi Laboratories Inc. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
1,085
1,749
2,160
1,017
733
409
Depreciation, Depletion & Amortization
2,697
2,108
1,833
1,620
1,689
1,631
Other Funds
2
3
3
2
2
1,452
Funds from Operations
1,544
4,888
3,592
2,169
2,612
583
Changes in Working Capital
3,028
171
367
778
148
809
Net Operating Cash Flow
4,572
5,059
3,225
2,947
2,760
1,392
Capital Expenditures
3,434
725
333
2,453
717
Sale of Fixed Assets & Businesses
36
3
81
13
1
Purchase/Sale of Investments
416
117
75
5
509
Net Investing Cash Flow
3,785
844
221
2,418
1,228
Cash Dividends Paid - Total
343
343
343
324
381
Issuance/Reduction of Debt, Net
20
19
12
1
-
Net Financing Cash Flow
365
365
1,358
329
385
Net Change in Cash
470
4,024
1,342
206
1,285
Free Cash Flow
1,154
4,403
2,937
875
2,103
Other Sources
29
-
-
15
-
Change in Capital Stock
-
-
1,000
-
-
Exchange Rate Effect
48
174
304
6
138
Other Uses
-
5
44
-
-

About Kawasumi Laboratories

View Profile
Address
Shinagawa Intercity Tower B, 9/F
Tokyo Tokyo 108
Japan
Employees -
Website http://www.kawasumi.jp
Updated 07/08/2019
Kawasumi Laboratories, Inc. engages in the manufacture and sale of medical devices and pharmaceuticals. It operates through the following segments: Blood Transfusion and Endovascular; and Hemodialysis and Plasmapheresis. The Blood Transfusion and Endovascular segment produces blood bags, blood collection kit, administration kit, catheter and stent-graft.